Pharmacia & Upjohn sues FDA for denying Rogaine exclusivity.
This article was originally published in The Tan Sheet
Executive Summary
PHARMACIA & UPJOHN SEEKS REVERSAL OF ROGAINE EXCLUSIVITY DECISION in a suit brought against FDA on April 12. Filed in U.S. District Court for the Western District of Michigan, the lawsuit asks the court to "reverse FDA's adverse ruling on Rogaine market exclusivity...and order FDA to defer approval of competing nonprescription products containing minoxidil."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning